Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : sciclone pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: JEB who wrote (1112)	7/29/2003 6:29:51 PM
From: Skywatcher	Respond to of 1137

I don't know...don't know if anyone does....I guess the fact that the SARS thing is much less of a problem certainly makes us look good anyway..... CC

To: JEB who wrote (1112)	9/24/2003 10:04:57 AM
From: Skywatcher	Respond to of 1137

FIRST OF TWO PHASE 3 HEPATITIS C TRIALS SAN MATEO, CA – September 24, 2003 – SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) announced today that it has completed the planned enrollment of 500 patients in the first of its two phase 3 hepatitis C (HCV) clinical trials evaluating its lead immune system enhancing drug ZADAXIN. SciClone intends to complete enrollment of the planned 500 patients for its second phase 3 HCV clinical trial by the end of the first quarter of 2004. SciClone expects all 1,000 patients to have completed the 12-month course of therapy and six–month follow up observation period by the second half of 2005. ZADAXIN is the only non-interferon based new drug that we know of currently in phase 3 HCV clinical trials in the U.S. According to the National Institutes of Health, an estimated 4 million people in the U.S. have been infected with the hepatitis C virus. “Reaching our enrollment target is a major milestone and demonstrates our progress with the clinical and regulatory development of ZADAXIN,” commented Eduardo B. Martins, M.D., Ph.D., Vice President, Medical Affairs of SciClone Pharmaceuticals. “SciClone’s trials are designed to demonstrate that ZADAXIN, in combination with pegylated interferon alpha, is effective in treating HCV patients who have not responded to prior therapy with standard of care treatment.” Current standard therapy for treatment of HCV patients is a 12-month course of pegylated interferon alpha plus ribavirin, a combination only effective for approximately half of all HCV patients in the U.S. Patients who fail initial therapy are termed “non-responders.” There is no therapy approved by the U.S. Food and Drug Administration for the re-treatment of these difficult to treat non-responders. SciClone’s objective is to have ZADAXIN in combination with pegylated interferon alpha become the first FDA approved therapy for the treatment of non-responders. About SciClone’s Phase 3 Hepatitis C Trials SciClone is conducting two 500 patient clinical trials treating hepatitis C patients who have failed to respond to prior FDA-approved HCV therapies. The two trials are multi-center, randomized and double-blinded studies. The first trial includes HCV patients without evidence of cirrhosis of the liver and the second trial includes HCV patients with mild cirrhosis of the liver. In each of the clinical trials, patients are assigned to a 12-month course of either ZADAXIN and pegylated interferon alpha or placebo and pegylated interferon alpha. After completing treatment, the patients will be followed for a six-month observation period. These treatment and follow-up periods are designed to be consistent with the FDA standard for demonstrating sustained response to HCV therapy. Successful completion of both of these trials would likely be necessary for FDA approval. Primary endpoints are a sustained virological response (clearance of HCV from the blood) and an improvement in the liver histological activity index measured at the end of the six-month observation period. CC

To: JEB who wrote (1112)	10/8/2003 11:52:15 AM
From: Skywatcher	Respond to of 1137

So no one has a take on the 2100 calls bought at .40 for December 7.50's???????? Now the 5's I could certainly understand considering they were bought the day of the 6 million shares issuance while the stock was FALLING to 8......December just around the corner and someone invests $600K into those? most curious that someone really knows something we don't....like that is unusual for this stock, right.... The $850K from the government to fight the TB epidemic is a nice boost...since that is just about as potentially profitable as Hep B&C......doing the research in Russia though?......we'll see CC